gptkbp:instanceOf
|
antiviral drug
|
gptkbp:approvalYear
|
1999
|
gptkbp:approvedBy
|
gptkb:FDA
|
gptkbp:ATCCode
|
J05AH01
|
gptkbp:brand
|
gptkb:Relenza
|
gptkbp:CASNumber
|
139110-80-8
|
gptkbp:chemicalFormula
|
C12H20N4O7
|
gptkbp:contraindication
|
asthma
chronic obstructive pulmonary disease
|
gptkbp:developedBy
|
GlaxoSmithKline
|
gptkbp:discoveredBy
|
gptkb:Mark_von_Itzstein
|
gptkbp:eliminationHalfLife
|
2.5-5.1 hours
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
https://www.w3.org/2000/01/rdf-schema#label
|
zanamivir
|
gptkbp:KEGGID
|
D08645
|
gptkbp:legalStatus
|
expired
prescription only
|
gptkbp:mechanismOfAction
|
neuraminidase inhibitor
|
gptkbp:meltingPoint
|
>180°C
|
gptkbp:molecularWeight
|
332.31 g/mol
|
gptkbp:origin
|
gptkb:Australia
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL123
60855
DB00558
|
gptkbp:routeOfAdministration
|
inhalation
|
gptkbp:sideEffect
|
nausea
headache
cough
bronchospasm
|
gptkbp:UNII
|
4L6J16JP0R
|
gptkbp:usedFor
|
gptkb:influenza_A
gptkb:influenza_B
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
gptkbp:bfsParent
|
gptkb:Influenza_A
gptkb:Influenza_virus
gptkb:influenza_B_virus
gptkb:H5N1
gptkb:H7N9
gptkb:Influenza_A_virus
gptkb:Seasonal_influenza
|
gptkbp:bfsLayer
|
5
|